Loading…
for educational and safety purposes
RS-67333 and PF-04995274 both come up in the same conversations; they overlap on Serotonin and Acetylcholine. RS-67333: RS-67333 is a selective, high-affinity partial agonist of the serotonin 5-HT4 receptor that has become the reference pharmacological tool for probing the pro-cognitive and disease-modifying potential of 5-HT4 activation in the central nervous system. PF-04995274: PF-04995274 is a selective, brain-penetrant 5-HT4 receptor partial agonist originally developed by Pfizer that has become the leading clinical probe for pro-cognitive and antidepressant effects of central 5-HT4 activation in humans.
RS-67333 is a selective, high-affinity partial agonist of the serotonin 5-HT4 receptor that has become the reference pharmacological tool for probing the pro-cognitive and disease-modifying potential of 5-HT4 activation in the central nervous system. Unlike the marketed gastrointestinal 5-HT4 agonists, RS-67333 crosses the blood-brain barrier readily and has been studied almost exclusively in preclinical models of learning, memory, and Alzheimer's disease. Its signature finding is that chronic 5-HT4 stimulation shifts amyloid precursor protein processing toward the non-amyloidogenic alpha-secretase pathway, increasing release of the neurotrophic sAPPalpha fragment while lowering amyloid-beta. RS-67333 is an investigational research compound with no human clinical development and no approved use.
PF-04995274 is a selective, brain-penetrant 5-HT4 receptor partial agonist originally developed by Pfizer that has become the leading clinical probe for pro-cognitive and antidepressant effects of central 5-HT4 activation in humans. It advanced into experimental medicine studies in major depressive disorder, where short courses altered emotional and memory-related brain circuitry in ways distinct from a conventional selective serotonin reuptake inhibitor. In the RESTAND programme it increased hippocampal and parietal activity during memory encoding and produced early signals of mood improvement without the classic negative-bias shift seen with citalopram. It remains an investigational compound and is not approved for any indication.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
High-affinity partial agonist; Gs-coupled stimulation of adenylyl cyclase and cyclic AMP
Selective, brain-penetrant partial agonist; Gs-coupled cyclic AMP signalling
Promotes non-amyloidogenic cleavage and sAPPalpha release
Facilitates evoked acetylcholine output
Reduces glial reactivity after chronic dosing
Reduces self-reported depression, anxiety, and negative affect early
Increases activation to novel versus familiar stimuli in patients
Augments activation during emotional face processing
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.